Strategy: Building and Sustaining Competitive Advantage

Bharat N. Anand; Stephen P. Bradley; Pankaj   Ghemawat; Tarun   Khanna; Cynthia A. Montgomery; Michael E. Porter; Jan W. Rivkin; Michael G. Rukstad; John R. Wells; David B. Yoffie

Class Lecture | June 2005 (Revised September 2008)

Strategy: Building and Sustaining Competitive Advantage

by Bharat N. Anand, Stephen P. Bradley, Pankaj Ghemawat, Tarun Khanna, Cynthia A. Montgomery, Michael E. Porter, Jan W. Rivkin, Michael G. Rukstad, John R. Wells and David B. Yoffie

Abstract

It's great to have a blockbuster quarter or a revolutionary product or service, but true business excellence demands sustainability. Maintaining your competitive advantage requires a strategy that makes your business unique and carries you forward as the world around you changes. What makes a winning, sustainable strategy? Strategy: Building and Sustaining Competitive Advantage is a multimedia resource developed by ten faculty members in the Strategy Department at Harvard Business School. Included in this resource are faculty presentation, animated frameworks, print- and video-based case studies, and workbooks to help business leaders formulate action plans specific to their own companies.

Keywords: Competitive Advantage;

Format: Multimedia

32400 length of video

Purchase

Citation:

"Strategy: Building and Sustaining Competitive Advantage." Harvard Business School Class Lecture 705-509, June 2005. (Revised September 2008.)

While there is evidence about labor market discrimination based on race, religion, and gender, we know little about whether physical appearance leads to discrimination in labor market outcomes. We deploy a randomized experiment on 1,000 respondents in India between April and May 2020 to investigate how “looks” affect labor market outcomes. Using machine learning and computer face rendering techniques, we simulate North, South, and Northeastern Indian faces and randomize two waves of treatments where we attach faces with otherwise identical CVs. However, the second wave also contains a vignette where we provide respondents with information about the incidence of discrimination. We focus on Northeastern Indian faces that resemble those in China to focus on the potential for discrimination that has historically been present in anecdotal accounts. While we do not find evidence of discrimination against Northeastern faces in the first wave, we do so in the second among those who do not see the vignette. We provide suggestive evidence that these results are consistent with the presence of homophily under limited attention.

Pallak Seth, Group CEO of PDS Multinational Fashions, is contemplating options to bring better collaboration across his global apparel supply chain platform. PDS, a group of 50-plus subsidiary companies, each led by its own CEO and with different apparel industry specialties, has grown rapidly over the past decade, yet the industry is increasingly competitive and challenges remain constant. Looking for ways to reach the Group’s 2023 goals of $2 billion in revenue, Seth and his executive board are considering two ways to increase collaboration and reward performance: a joint P&L approach to drive partnerships across the subsidiaries and an employee stock option plan, to unlock value across the Group.

Case | HBS Case Collection | September 2020

Minerva 2004: Discovery

John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for testing new drugs that was orders of magnitude faster than traditional approaches. Using this process, they had discovered the mechanism that caused 96% of all breast cancers and identified families of small molecule therapeutics that were effective in blocking this mechanism in live cells in the laboratory. Moreover, Bamdad did not think it would be long before the company could offer an early warning diagnostic for breast cancer, which would allow less invasive treatment of the condition. The company had filed several families of patent applications in support of these claims, but the challenge was funding. To date, Bamdad had relied on Federal Government grants and angel investors to fund the research, but the next steps would require much larger investment. Should Minerva seek to commercialize its drug development technology to help fund the riskier steps of drug development? Should it focus on a diagnostic which would make current treatments more effective? Should it license its small molecule therapeutics to one of the many well-funded companies seeking cures for cancer? Or should Bamdad raise capital to support tests in mice in order to reach the Federal Drug Administration IND (Investigational New Drug) application stage of drug discovery? This would allow clinical trials in humans, which would require more capital, but an IND would increase the value of Minerva’s intellectual capital substantially. What should Bamdad do?

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry;

Citation:

Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020. View Details

Cite View Details Educators Purchase

Faculty & Research

Strategy: Building and Sustaining Competitive Advantage

Abstract

Citation:

About the Authors

More from these Authors